Timothy C. Biggs
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Timothy C. Biggs has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Ali A. Salamat
Department of Otolaryngology/Head & Neck Surgery, University Hospital Southampton NHS Foundation Trust, Southampton, UK; Academic Unit of Clinical and Experimental Sciences, University of Southampton Faculty of Medicine, Southampton, UK
1 shared publication C. Faris
Nottingham Hospitals NHS Foundation Trust Nottingham UK
1 shared publicationC. Repanos
Portsmouth Hospitals NHS Trust Portsmouth UK
1 shared publication- Christopher Schulz
Department of Ophthalmology, Portsmouth Hospitals University NHS Trust, Cosham, Portsmouth, UK
1 shared publication J.H. Bird
Department of ENT Surgery, Portsmouth Hospitals NHS Trust, Portsmouth, UK; Department of Otolaryngology, University Hospital Southampton NHS Foundation Trust, Southampton, UK
1 shared publicationN. Lower
University of Southampton Southampton UK
1 shared publication
Latest Publications
- Open Access
- 27 October 2026
- Published by MDPI AG in Biomolecules
- Vol. 16 (11) , 1564
Dual Antimicrobial and Immunomodulatory Activities of a Bioengineered Reactive Oxygen Species Releasing Gel Against Multidrug-Resistant Staphylococcus aureus
In this study, we evaluated the antimicrobial and immunomodulatory properties of a novel bioengineered reactive oxygen species (ROS) gel that releases sustained, low concentrations of hydrogen peroxide (H2O2) upon hydration. The efficacy of the ROS gel was assessed against a multidrug-resistant clinical isolate of Staphylococcus aureus, and its effects on host defence were evaluated using human nasal epithelial cells and mast cells. The ROS gel significantly reduced Staphylococcus aureus biofilm viability while simultaneously upregulating genes involved in innate and adaptive host defence. Sustained H2O2 release enhanced the expression of antimicrobial peptides, toll-like receptor 4, and transcription factors associated with Th17 (RORC) and Th2 (GATA3) immune responses. In addition, the ROS gel modulated the expression of matrix metalloproteinases (MMP7 and MMP9) and IL10, suggesting a role in tissue remodelling and resolution of inflammation. These findings demonstrate that the ROS gel exerts dual therapeutic effects by directly inhibiting bacterial growth while modulating host transcriptional immune-associated gene responses. Harnessing ROS-based therapies may reduce reliance on conventional antibiotics and help limit the progression of antimicrobial resistance.
- 27 October 2026
- Published by MDPI AG in Biomolecules
- Vol. 16 (11) , 1564
Open AccessDual Antimicrobial and Immunomodulatory Activities of a Bioengineered Reactive Oxygen Species Releasing Gel Against Multidrug-Resistant Staphylococcus aureus
In this study, we evaluated the antimicrobial and immunomodulatory properties of a novel bioengineered reactive oxygen species (ROS) gel that releases sustained, low concentrations of hydrogen peroxide (H2O2) upon hydration. The efficacy of the ROS gel was assessed against a multidrug-resistant clinical isolate of Staphylococcus aureus, and its effects on host defence were evaluated using human nasal epithelial cells and mast cells. The ROS gel significantly reduced Staphylococcus aureus biofilm viability while simultaneously upregulating genes involved in innate and adaptive host defence. Sustained H2O2 release enhanced the expression of antimicrobial peptides, toll-like receptor 4, and transcription factors associated with Th17 (RORC) and Th2 (GATA3) immune responses. In addition, the ROS gel modulated the expression of matrix metalloproteinases (MMP7 and MMP9) and IL10, suggesting a role in tissue remodelling and resolution of inflammation. These findings demonstrate that the ROS gel exerts dual therapeutic effects by directly inhibiting bacterial growth while modulating host transcriptional immune-associated gene responses. Harnessing ROS-based therapies may reduce reliance on conventional antibiotics and help limit the progression of antimicrobial resistance.
- 4 August 2013
- Published by Wiley in Clinical Otolaryngology
- Vol. 38 (5) , 410-415
Implementation of an evidence‐based acute tonsillitis protocol: Our experience in one hundred and twenty‐six patients
- 4 August 2013
- Published by Wiley in Clinical Otolaryngology
- Vol. 38 (5) , 410-415
Implementation of an evidence‐based acute tonsillitis protocol: Our experience in one hundred and twenty‐six patients